Top View
- Mobilization Failure in Hematopoietic Stem Cell Transplantation
- Are All Gfs Equal? How Say I?
- White Blood Cell Colony Stimulating Factors – Value & Balance Exchange Medical Benefit Drug Policy
- (G-Csfs) (Filgrastim, Lenograstim, Lipegfilgrastim and Pegfilgrastim): New Warning Regarding Aortitis
- Clinical Biology and Potential Use of Thrombopoietin
- 5.01.551 Granulocyte Colony-Stimulating Factor (G-CSF) Use in Adult
- Filgrastim Label
- Colony Stimulating Factors NOTICE
- For Health Professionals Who Care for Cancer Patients
- (Filgrastim) on Bone Marrow Progenitor Cells
- Self-Administered Specialty Drug List
- Filgrastim-Sndz
- Study Protocol and Statistical Analysis Plan
- Clinical Medication Policy
- Nivestim, INN-Filgrastim
- Medications Used in Sarcoma Treatment
- Integrated Safety Profile of Selinexor in Multiple Myeloma
- White Blood Cell Growth Factors
- Human Granulocyte-Colony Stimulating Factor (G-CSF)/Stem Cell Factor (SCF) Fusion Proteins: Design, Characterization and Activity
- Haematological Malignancies
- V33n6a08.Pdf
- List Item Filgrastim Hexal : EPAR
- Granulocyte Colony-Stimulating Factor Progenitors After Treatment
- A Randomized Study Comparing Filgrastim Versus Lenograstim Versus Molgramostim Plus Chemotherapy for Peripheral Blood Progenitor
- NEUPOGEN® (Filgrastim) Injection, for Subcutaneous Or Intravenous Use Prefilled Syringe Initial U.S
- NCI Protocol
- A Phase I Study of Recombinant Human Leukemia Inhibitory Factor in Patients with Advanced Cancer1
- Pegfilgrastim, a Sustained-Duration Form of Filgrastim, Significantly
- The Incidence and Clinical Features of Pegylated Filgrastim-Induced Acute
- Pegfilgrastim, ( Neulasta), Amgen Incorporated
- 6902.Full.Pdf
- Colony Stimulating Factors
- In Comparison with Neupogen
- Which One Is More Effective, Filgrastim Or Lenograstim, During
- Thrombopoietin Receptor Agonists in the Treatment of Chronic Immune
- Pegfilgrastim), Leukine® (Sargramostim), Granix (Tbo-Filgrastim
- Improving Access to Cancer Care a First Analysis of Pharmaceutical Company Actions in Low- and Middle-Income Countries
- Product Information for Auspar Lonquex Lipegfilgrastim (Rbe) Teva Pharma Australia Pty Ltd, PM- 2014-03142-1-4 Final 23 February 2016
- Lonquex, INN-Lipegfilgrastim
- Filgrastim (Neupogen, Nivestym, Zarxio)
- Filgrastim And&Sol
- Use of Thrombopoietin in Combination with Chemotherapy and Granulocyte Colony-Stimulating Factor for Peripheral Blood Progenitor Cell Mobilization
- Cost-Effectiveness and Budgetary Impact of Lipegfilgrastim for The
- Please Refer to Figure 3 in Main Manuscript
- Thrombopoietic Factors in Chronic Bone Marrow Failure States: the Platelet Problem Revisited
- 3.2.2 Granulocyte-Colony Stimulating Factors, Pulmonary Haemorrhage
- Pcn17 Cost Effectiveness of Primary Prophylaxis
- Colony Stimulating Factors: Filgrastim (Neupogen®); Filgrastim-Aafi
- Stem Cell Mobilization Protocols: Filgrastim Vs. Mozobil Lily C
- Filgrastim HEXAL, INN-Filgrastim
- Role of Lipegfilgrastim in the Management of Chemotherapy-Induced Neutropenia
- G-CSF and Thrombopoietin
- The Regulatory Role of Non-Hematopoietic Bone Marrow Cells on Hematopoiesis in Steady-State and Inflammation
- White Blood Cell Colony Stimulating Factors – Commercial Medical Benefit Drug Policy
- STEM CELL BIOLOGY and HEMATOPOIETIC GROWTH FACTORS David J
- Effects of Filgrastim on Gene Expression of Cholinergic System in the Rat Hippocampus
- Stem Cell Factor) in Patients Who Had Failed a Prior Mobilization with filgrastim (Granulocyte Colony-Stimulating Factor) Alone Or with Chemotherapy Plus filgrastim